Study to Assess Antioxidant Efficacy of Spirulina on oxLDL and Lipids Metabolism on Subjects With Metabolic Syndrome

Metabolic Syndrome Clinical Trial

— SPIROX  

Official title:

Pilot Study to Assess Antioxidant Efficacy of a Spirulina Water Extract on Oxidized LDL Status and Lipids Metabolism on Subjects With Metabolic Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02817620
• Other study ID #: PEC15039
• Status: Completed
• Phase: N/A
• First received: June 27, 2016
• Last updated: September 15, 2017
• Start date: August 24, 2016
• Est. completion date: September 14, 2017

Study information

• Verified date: September 2017
• Source: Algosource
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this pilot study is to assess the beneficial effect of a spirulina water extract (product named Spirulysat®) compared to a placebo in the blood level ratio of oxidized LDL / total LDL cholesterol in subjects with metabolic syndrome after 12 weeks of consumption

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: September 14, 2017
• Est. primary completion date: September 14, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

To be eligible to the study, male and female volunteers will have to fulfil the following criteria (assessment based on the medical examination performed at V0 with a checking at V1):

• Age between 18 and 65 years (limits included),

• BMI between 25 and 35 kg/m² (limits included),

• With metabolic syndrome defined as central obesity : waist circumference > 94 cm for man and > 80 cm for woman associated to at least 2 observed criteria among : Fasting blood triglycerides > 1.5 g/L and/or Fasting blood HDL cholesterol < 0.4 g/L for man and < 0.5 g/L for woman and/or Fasting blood glucose level > 1 g/L and/or Arterial pressure > 130/85 mmHg or under antihypertensive treatment,

• For women : non menopausal with the same reliable contraception since at least 3 months before the beginning of the study and agreeing to keep it during the entire duration of the study (condom with spermicide gel accepted) or menopausal without or with hormone replacement therapy started at stable dose since at least 3 months before the beginning of the study and agreeing to keep it during the entire duration of the study,

• Weight stable with +/- 5 % in the last 3 months ,

• Non smoking or with tobacco consumption < 10 cigarettes / day,

• Good general and mental health with in the opinion of the investigator : no clinically significant and relevant abnormalities of medical history or physical examination,

• Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form,

• Affiliated with a social security scheme,

• Agree to be registered on the volunteers in biomedical research file,

After V0 biological analysis the subjects will be eligible to the study on the following criterion :

• Blood fasting lipid profile not requiring therapeutic intervention meaning professional recommendations (AFSSAPS, 2005).

A re-screening can occur from 2 months after the exit of the study for failure to comply with one or more of the inclusion criteria listed above.

Exclusion Criteria:

Volunteers with the following criteria will be considered as non eligible to the study (assessment based on the medical examination performed at V0 with a checking at V1):

• Suffering from a metabolic disorder such as diabetes, uncontrolled thyroidal trouble...,

• Suffering from a severe chronic disease (e.g. cancer, HIV, renal failure, hepatic or biliary disorders ongoing, chronic inflammatory digestive disease, arthritis or other chronic respiratory trouble, etc.) or gastrointestinal disorders found to be inconsistent with the conduct of the study by the investigator (e.g. celiac disease),

• With a history of ischemic cardiovascular event,

• Having undergone recent surgical procedure (less than 6 months),

• Suffering from an uncontrolled hypertension (systolic blood pressure = 160 mmHg and/or diastolic blood pressure = 100 mmHg),

• With a known or suspected food allergy or intolerance or hypersensitivity to any of the study products' ingredient,

• Pregnant or lactating women or intending to become pregnant within 4 months ahead,

• Under cholesterol and/or lipid-lowering treatment (e.g. statins, fibrates, ezetimibe, bile acid sequestrants, niacin, etc.) or stopped less than 3 months before the V0 visit,

• Under medication which could affect blood lipid parameters (e.g. long-term corticosteroid systemic drug, systemic antibodies, androgens or enzyme inducers, etc.) or stopped less than 3 months before the V0 visit (antihypertensive stable long-term treatment tolerated),

• Regular intake of dietary supplements or "functional foods" which are known to have an impact on lipid metabolism (e.g. rich in plant stanol or sterol like PRO-ACTIV or DANACOL products, red yeast rice, policosanol, capsules containing omega-3 fatty acids from fish oils, etc.) or stopped less than 3 months before the V0 visit,

• Under treatment or dietary supplement which could significantly affect parameter(s) followed during the study according to the investigator or stopped in a too short period before the V0 visit,

• With significant change in food habits or in physical activity in the 3 months before the V0 visit or not agreeing to keep them unchanged throughout the study,

• With a current or planned in the next 4 months specific diet (hyper or hypocaloric, vegan, vegetarian...) or stopped less than 3 months before the V0 visit,

• With a personal history of anorexia nervosa, bulimia or significant eating disorders according to the investigator,

• Consuming more than 3 standard drinks of alcoholic beverage daily for men or 2 daily for women or not agreeing to keep his alcohol consumption habits unchanged throughout the study,

• Having a lifestyle deemed incompatible with the study according to the investigator including high level physical activity (defined as more than 10 hours of significant physical activity a week, walking excluded),

• Who made a blood donation in the 3 months before the V0 visit or intending to make it within 4 months ahead,

• Taking part in another clinical trial or being in the exclusion period of a previous clinical trial,

• Having received, during the last 12 months, indemnities for clinical trial higher or equal to 4500 euros,

• Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision,

• Presenting a psychological or linguistic incapability to sign the informed consent,

• Impossible to contact in case of emergency,

After V0 biological analysis the subjects will be considered as non eligible to the study on the following criteria :

• Fasting blood triglycerides > 3.5 g/L (3.95 mmol/L),

• Blood ASAT, ALAT or GGT (Gamma Glutamyl Transferase) > 3xULN (Upper Limit of Normal),

• Blood urea > 12.11 mmol/L (value corresponding to 1.5xULN) or creatinine > 125 µmol/L,

• Blood hsCRP > 10 mg/L,

• Complete blood count with clinically significant abnormality according to the investigator.

A re-screening can occur from 2 months after the exit of the study for failure to comply with one or more of the exclusion criteria listed above.

Related Conditions & MeSH terms

• Metabolic Syndrome
• Metabolic Syndrome X
• Syndrome

Intervention

Dietary Supplement:
• Spirulysat®

• Placebo

Locations

Country	Name	City	State
France	Biofortis Mérieux NutriSciences Clinical Investigation Center	Saint Herblain

Sponsors (2)

Lead Sponsor	Collaborator
Algosource	Biofortis Mérieux NutriSciences

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Bile acids levels in stool (desoxycholic acid, lithocholic acid, cholic acid, chenodesoxycholic acid, bile salt, ursodesoxycholic acid)		Baseline
Other	Bile acids levels in stool (desoxycholic acid, lithocholic acid, cholic acid, chenodesoxycholic acid, bile salt, ursodesoxycholic acid)		6 weeks
Other	Bile acids levels in stool (desoxycholic acid, lithocholic acid, cholic acid, chenodesoxycholic acid, bile salt, ursodesoxycholic acid)		12 weeks
Other	Short chain fatty acids levels in stool (acetic acid, n-butyric acid, iso-butyric acid, n-valerianic acid, propionic acid)		Baseline
Other	Short chain fatty acids levels in stool (acetic acid, n-butyric acid, iso-butyric acid, n-valerianic acid, propionic acid)		6 weeks
Other	Short chain fatty acids levels in stool (acetic acid, n-butyric acid, iso-butyric acid, n-valerianic acid, propionic acid)		12 weeks
Other	Blood level of Glutathione peroxidase		Baseline
Other	Blood level of Glutathione peroxidase		6 weeks
Other	Blood level of Glutathione peroxidase		12 weeks
Other	Superoxide dismutase blood level		Baseline
Other	Superoxide dismutase blood level		6 weeks
Other	Superoxide dismutase blood level		12 weeks
Other	Catalase blood level		Baseline
Other	Catalase blood level		6 weeks
Other	Catalase blood level		12 weeks
Other	Intestinal microbiota (bacterial DNA extraction in stool)		Baseline
Other	Intestinal microbiota (bacterial DNA extraction in stool)		12 weeks
Other	PON-1 (paraoxonase-1) in blood (arylesterase activity)		Baseline
Other	PON-1 (paraoxonase-1) in blood (arylesterase activity)		12 weeks
Other	Body weight	Defined as the difference V2 (6 weeks) - V1 (baseline) in kg	6 weeks
Other	Body weight	Defined as the difference V3 (12 weeks) - V1 (baseline) in kg	12 weeks
Other	Total energy intake	Defined as the difference V2 (6 weeks) - V1 (baseline) in kcal/day	6 weeks
Other	Total energy intake	Defined as the difference V3 (12 weeks) - V1 (baseline) in kcal/day	12 weeks
Other	Percentage of energy intake from fat	Defined as the difference V2 (6 weeks) - V1 (baseline) in %	6 weeks
Other	Percentage of energy intake from fat	Defined as the difference V3 (12 weeks) - V1 (baseline) in %	12 weeks
Other	Percentage of energy intake from carbohydrates	Defined as the difference V2 (6 weeks) - V1 (baseline) in %	6 weeks
Other	Percentage of energy intake from carbohydrates	Defined as the difference V3 (12 weeks) - V1 (baseline) in %	12 weeks
Other	Percentage of energy intake from protein	Defined as the difference V2 (6 weeks) - V1 (baseline) in %	6 weeks
Other	Percentage of energy intake from protein	Defined as the difference V3 (12 weeks) - V1 (baseline) in %	12 weeks
Other	Dietary fiber intake	Defined as the difference V2 (6 weeks) - V1 (baseline) in g/day (absolute quantities)	6 weeks
Other	Dietary fiber intake	Defined as the difference V3 (12 weeks) - V1 (baseline) in g/day (absolute quantities)	12 weeks
Other	Saturated fatty acid intake	Defined as the difference V2 (6 weeks) - V1 (baseline) in g/day (absolute quantities)	6 weeks
Other	Saturated fatty acid intake	Defined as the difference V3 (12 weeks) - V1 (baseline) in g/day (absolute quantities)	12 weeks
Other	Mono-unsaturated fatty acid intake	Defined as the difference V2 (6 weeks) - V1 (baseline) in g/day (absolute quantities)	6 weeks
Other	Mono-unsaturated fatty acid intake	Defined as the difference V3 (12 weeks) - V1 (baseline) in g/day (absolute quantities)	12 weeks
Other	Poly-unsaturated fatty acid intake	Defined as the difference V2 (6 weeks) - V1 (baseline) in g/day (absolute quantities)	6 weeks
Other	Poly-unsaturated fatty acid intake	Defined as the difference V3 (12 weeks) - V1 (baseline) in g/day (absolute quantities)	12 weeks
Other	Heart rate (bpm)		Pre-inclusion (V0), Baseline (V1), 6 weeks (V2) and 12 weeks (V3)
Other	Systolic blood pressure (mmHg)		Pre-inclusion (V0), Baseline (V1), 6 weeks (V2) and 12 weeks (V3)
Other	Diastolic blood pressure (mmHg)		Pre-inclusion (V0), Baseline (V1), 6 weeks (V2) and 12 weeks (V3)
Primary	Changes in the ratio of fasting blood concentrations oxidized LDL / total LDL cholesterol	Defined as the difference V3 (12 weeks) - V1 (baseline) in mU/g	12 weeks
Secondary	Changes in the ratio of fasting blood concentrations oxidized LDL / total LDL cholesterol	Defined as the difference V2 (6 weeks) - V1 (baseline) in mU/g	6 weeks
Secondary	Changes in fasting blood oxidized LDL level	Defined as the difference V2 (6 weeks) - V1 (baseline) in mU/L	6 weeks
Secondary	Changes in fasting blood oxidized LDL level	Defined as the difference V3 (12 weeks) - V1 (baseline) in mU/L	12 weeks
Secondary	Changes in fasting blood concentrations of total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides	Defined as the difference V2 (6 weeks) - V1 (baseline) in g/L	6 weeks
Secondary	Changes in fasting blood concentrations of total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides	Defined as the difference V3 (12 weeks) - V1 (baseline) in g/L	12 weeks
Secondary	Changes in fasting blood concentrations of hsCRP	Defined as the difference V2 (6 weeks) - V1 (baseline) in mg/L	6 weeks
Secondary	Changes in fasting blood concentrations of hsCRP	Defined as the difference V3 (12 weeks) - V1 (baseline) in mg/L	12 weeks
Secondary	Changes in fasting blood concentration of total free fatty acid	Defined as the difference V2 (6 weeks) - V1 (baseline) in mmol/L	6 weeks
Secondary	Changes in fasting blood concentration of total free fatty acid	Defined as the difference V3 (12 weeks) - V1 (baseline) in mmol/L	12 weeks
Secondary	Changes in fasting blood concentration of alkaline phosphatase	Defined as the difference V2 (6 weeks) - V1 (baseline) in µkat/L	6 weeks
Secondary	Changes in fasting blood concentration of alkaline phosphatase	Defined as the difference V3 (12 weeks) - V1 (baseline) in µkat/L	12 weeks
Secondary	Changes in fasting blood concentrations of ASAT (Aspartate aminotransferase) and ALAT (alanine aminotransferase)	Defined as the difference V2 (6 weeks) - V1 (baseline) in µkat/L	6 weeks
Secondary	Changes in fasting blood concentrations of ASAT (Aspartate aminotransferase) and ALAT (alanine aminotransferase)	Defined as the difference V3 (12 weeks) - V1 (baseline) in µkat/L	12 weeks
Secondary	Changes in fasting blood concentration of total antioxidant status	Defined as the difference V2 (6 weeks) - V1 (baseline) in mmol/L	6 weeks
Secondary	Changes in fasting blood concentration of total antioxidant status	Defined as the difference V3 (12 weeks) - V1 (baseline) in mmol/L	12 weeks
Secondary	Changes in concentration of urinary isoprostane (F2-isoprostane alpha)	Defined as the difference V2 (6 weeks) - V1 (baseline) in ng/mL	6 weeks
Secondary	Changes in concentration of urinary isoprostane (F2-isoprostane alpha)	Defined as the difference V3 (12 weeks) - V1 (baseline) in ng/mL	12 weeks